NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of BioScrip, Inc. (NASDAQGM:BIOS) concerning possible violations of federal securities laws. On March 8, 2018, BioScrip released its preliminary fourth quarter and full year financial results and disclosed that the Company had begun an internal accounting review after identifying “internal control deficiencies in connection with account reconciliations for certain asset and liability accounts.” The Company also announced that it “has identified and will report a material weakness related to certain spreadsheets used to calculate periodic adjustments to” certain accounts. Upon this news, shares of BioScrip were down more than 15% on intraday trading on March 8, 2018. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.